Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | BCAT2 | O15382 | 9/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23237561 | 0.81 | THRB (0.65) | THRBMAPTLMNABCAT2HPGD | |
| SCHEMBL23209156 | 0.81 | BCAT2 (0.72) | THRBMAPTLMNABCAT2HPGD | |
| SCHEMBL23267317 | 0.80 | BCAT2 (0.70) | THRBMAPTLMNABCAT2HPGD | |
| SCHEMBL263739 | 0.76 | BCAT2 (1.00) | THRBMAPTLMNABCAT2HPGD | |
| SCHEMBL265344 | 0.76 | HPGD (1.00) | THRBMAPTLMNABCAT2HPGD | |
| SCHEMBL19119395 | 0.75 | BCAT2 (0.76) | THRBMAPTLMNABCAT2HPGD | |
| SCHEMBL27273135 | 0.75 | BCAT2 (0.76) | THRBMAPTLMNABCAT2HPGD | |
| SCHEMBL263943 | 0.74 | KDM4E (1.00) | THRBMAPTLMNABCAT2HPGD | |
| SCHEMBL15646362 | 0.71 | THRB (0.50) | THRBMAPTLMNABCAT2HPGD | |
| SCHEMBL264414 | 0.69 | BCAT2 (0.65) | THRBMAPTLMNABCAT2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136336-B2 | Thienopyrimidones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-10-05 | — | — | US | disclosed |
| US-20210107918-A1 | Novel Thienopyrimidones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107918-A1 | Novel Thienopyrimidones | TRPA1, TRPV1, TRPV2 | THRB 1255/4885MAPT 287/4885LMNA 4265/4885 |
| US-11136336-B2 | Thienopyrimidones | TRPA1, TRPV1, TRPV2 | THRB 1678/4885MAPT 234/4885LMNA 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.